A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis Clinical Trial

— FEXPRESAR  

Official title:

A Phase IIIb, Single-center, Double-blind, Two-arms, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of 2-day Pre-treatment With Fexofenadine in Patients Suffering From Seasonal Allergic Rhinitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05692154
• Other study ID #: LPS17180
• Secondary ID: U1111-1278-3949
• Status: Completed
• Phase: Phase 3
• Start date: January 23, 2023
• Est. completion date: March 14, 2023

Study information

• Verified date: November 2023
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a proof-of-concept study to demonstrate if a daily dose of a 2-days pre-treatment of Fexofenadine 180mg is effective in alleviating the AR symptoms and to assess the additional benefit to the patient in terms of preventing Allergic Rhinitis (AR) symptoms. The total study duration per participant is expected at least 4 months, depending on the timing of the screening visit. 5 visits are planned, screening, confirmation inclusion challenge, randomization visit, challenge and end of study visit.

Description:

The end of the study is defined as the date of the last visit of the last participant in the study. A participant is considered to have completed the study if he/she has completed all visits of the study including Visit 5 (Day 5).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 94
• Est. completion date: March 14, 2023
• Est. primary completion date: March 14, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Participants are eligible to be included in the study only if all of the following

criteria apply:

• Participant is willing to provide written informed consent.
• Adult participants (18 to 80 years old) suffering from SAR provoked by Ragweed pollen.
• Participants having a TNSS-3 =4 (with 3 nasal symptoms) at first pollen challenge at Visit 2.
• Having a 2-year history of SAR with Positive skin prick test to Ragweed allergen at screening (with a wheal diameter at least 3 mm larger than that produced by the negative control).

Exclusion Criteria:

• History of anaphylaxis to Ragweed pollen History of asthma or exacerbations in the past 12 months requiring regular inhaled corticosteroids for greater than 4 weeks per year, any oral corticosteroid usage, any emergency department visit for asthma or any asthma-related hospitalization. Mild asthmatics treated only with pro re nata short-acting ß2agonists, less than 2 doses per week can be enrolled.
• History of chronic sinusitis, defined as a sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, and ear pain, pressure, or fullness.
• History of systemic disease affecting the immune system such as autoimmune diseases, immune complex disease, or immunodeficiency, where, in the opinion of the study physician, participation in the trial would pose a risk or significant effect on the immune system.
• Presence or history of drug hypersensitivity to fexofenadine and/or its excipients.
• Participants unable to stop the following forbidden treatments/nutriments prior to

pollen challenge:

• Antihistamines: within 3 days for first-generation antihistamines, within 2 days for second-generation antihistamines.
• Intranasal or inhaled corticosteroids: 7 days.
• Ocular, intranasal, or inhaled sodium cromoglycate: 14 days.
• High doses of systemic corticosteroids: 30 days.
• Leukotriene antagonists: 30 days.
• Intranasal or systemic decongestants: 3 days.
• Tricyclic antidepressants: 7 days.
• Any citrus fruits (grapefruit, orange, etc.) or their juices, as well as all fruit juices: 5 days.
• Aluminum-and-magnesium containing antacids: 7 days.
• Omalizumab/dupilumab: within 6 months
• Any contraindications to fexofenadine, according to the labeling.
• The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Related Conditions & MeSH terms

• Rhinitis
• Rhinitis, Allergic
• Rhinitis, Allergic, Seasonal
• Seasonal Allergic Rhinitis

Intervention

Drug:
• Fexofenadine
Fexofenadine oral tablet
• Placebo
Fexofenadine matching placebo oral tablet

Locations

Country	Name	City	State
Canada	Investigational Site Number : 1240001	Kingston	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Opella Healthcare Group SAS, a Sanofi Company

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC of the total nasal symptoms score (TNSS-3)	Area under the plasma concentration-time curve (AUC) of TNSS-3 The total nasal symptom score of 3 symptoms (TNSS-3: scale of each symptom is scored from 0 to 3): rhinorrhea, sneezing, and nasal itching scores.	from 0 hour to 6 hours at day 4
Secondary	AUC of total ocular symptoms score (TOSS) (0h-6h at day 4)	TOSS = Total Ocular Symptoms Score.	from 0 hour to 6 hours at day 4
Secondary	AUC of total nasal symptoms score (TNSS-3) (0h-12h at day 4)		from 0 hour to 12 hours at day 4
Secondary	AUC of total ocular symptoms score (TOSS) (0h-12h at day 4)		from 0 hour to 12 hours at day 4
Secondary	AUC of total nasal symptoms score (TNSS-3) (Day 1 to day 4)		from randomization (day 1 ) to day 4
Secondary	AUC of total ocular symptoms score (TOSS) (Day 1 to day 4)		from randomization (day 1) to day 4
Secondary	Percentage of participants with Adverse Events		from screening to day 5